Cumbre Pharmaceuticals Inc.

Schering Corporation

Pharmacopeia Inc.

Cumbre IP Ventures, L.p.

Keith P Minor

Zhenkun Ma

Charles Z Ding

Susan Harran

Jing Li

Yafei Jin

In Ho Kim

Jamie C Longgood

Ronald J Doll

Yong He

John J Baldwin

Viyyoor Moopil Girijavallabhan

F George Njoroge

Ge Li

Timothy J Guzi

Alan B Cooper

Dinanath F Rane

Patrick A Pinto

Carmen S Alvarez

Kartik M Keertikar

Ray Anthony James

Jagdish A Desai

Bancha Vibulbhan

Chia-Yu Huang

James J-s Wang

Hugh Y Zhu

Keith D Combrink

Bama Santhanam

Kevin B Alton

Wenqing Feng

Tze-Ming Chan

Swapan K Chowdhury

Anima Ghosal

Shmuel Zbaida

Robert M Iannucci

Timothy W Morris

Jamie Carol Longgood

Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Farnesyl protein transferase inhibitors as antitumor agents

The present invention relates to metabolites of tricyclic amides, and structurally related compounds, represented by the structural formula (I):  Also disclosed are methods of treatment of proliferative diseases and methods for inhibiting the abnormal growth of cells, and for inhibiting farnesyl protein transferase using the novel compounds.

Metabolites of tricyclic amides useful for inhibition of G-protein function and methods of treatment of proliferative diseases

Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.

Rifamycin derivatives effective against drug-resistant microbes

The present invention relates to rifamycin 3-iminomethylenyl (&#x2014;CH&#x2550;N&#x2014;) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (&#x2014;CH&#x2550;N&#x2014;) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

Rifamycin imino derivatives effective against drug-resistant microbes

Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C-C) forms): or their salts, hydrates or prodrugs thereof,wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG., provided L is not wherein Ris H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.

Rifamycin derivatives

Rifamycin derivatives having the following structure of general formula I (both hydroquinone and corresponding quinone (C-C) forms): or its salts, hydrates or prodrugs thereof; wherein a preferred Rcomprises hydrogen or acetyl and a prefered Rcomprises hydrogen, methyl or other lower alkyls; wherein asterik (*) denotes the carbon bearing the chiral center, wherein absolute configuration is assigned as R or S. Methods of preparation of the aforementioned rifamycin derivatives are also described. The compounds exhibit antimicrobial activities, including activities against drug-resistant microorganisms.

(R/S) rifamycin derivatives, their preparations and pharmaceutical compositions

Growing community of inventors

Dallas, TX, United States of America

Keith P Minor